Resistance to the skeletal muscle injury expressed by repeated treatment with compound a that has HMG-CoA reductase inhibitory activity

Journal of Toxicological Sciences

Volumn 32, Issue 1, 2007, Pages 9-18

  Tanaka, Kohji ^a   Kiyosawa, Naoki ^a   Honda, Kumi ^a   Sharyo, Satoru ^a   Ito, Kazumi ^a   Teranishi, Munehiro ^a   Manabe, Sunao ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

HMG CoA reductase inhibitory activity; Resistance; Skeletal muscle injury

Indexed keywords

2 METHYL BUTYRIC ACID 4 ([1,3]DIOXAN 5 YLMETHOXYIMINO) 8 [2 (4 HYDROXY 6 OXO TETRAHYDROPYRAN 2 YL) ETHYL] 7 METHYL 6 OXO 1,2,3,4,6,7,8,8A OCTAHYDRO NAPHTHALEN 1 YL ESTER; CCAAT ENHANCER BINDING PROTEIN; CREATINE KINASE; ESTER DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SODIUM 3,5 DIHYDROXY 7 [4 ([1,3]DIOXAN 5 YLMETHOXYIMINO) 8 [2 [(4 HYDROXY 6 OXO TETRAHYDRO 2H PYRAN 2 YL)]ETHYL] 7 METHYL 6 OXO 1,2,3,4,6,8,8A OCTAHYDRO NAPHTHYL]HEPTANOATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; ELECTROPHORESIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FOOD INTAKE; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION; GENE PROBE; GENETIC ANALYSIS; HISTOPATHOLOGY; MALE; MUSCLE INJURY; NECROSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; RECTUS FEMORIS MUSCLE; SKELETAL MUSCLE; STATISTICAL ANALYSIS;

RATTUS;

ANIMALS; BODY WEIGHT; CREATINE KINASE; DRUG RESISTANCE; EATING; GENE EXPRESSION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICROARRAY ANALYSIS; MUSCLE, SKELETAL; NAPHTHALENES; NECROSIS; NF-KAPPA B; RATS; RATS, INBRED F344; TRANSCRIPTIONAL ACTIVATION;

EID: 33847405292     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.32.9     Document Type: Article

References (30)

1. Barkett, M. and Gilmore, T.D. (1999): Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene, 18, 6910-6924.
2. Cai, D., Frantz, J.D., Tawa, N.E. Jr., Melendez, P.A., Oh, B.C., Lidov, H.G., Hasselgren, P.O., Frontera, W.R., Lee, J., Glass, D.J. and Shoelson, S.E. (2004): IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell, 119, 285-298.
3. Catani, M.V., Savini, I., Duranti, G., Caporossi, D., Ceci, R., Sabatini, S. and Avigliano, L. (2004): Nuclear factor kappaB and activating protein 1 are involved in differentiation-related resistance to oxidative stress in skeletal muscle cells. Free. Radic. Biol. Med., 37, 1024-1036.
4. Dichtl, W., Dulak, J., Frick, M., Alber, H.F., Schwarzacher, S.P., Ares, M.P., Nilsson, J., Pachinger, O. and Weidinger, F. (2003): HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 23, 58-63.
5. Gao, Z., Chiao, P., Zhang, X., Lazar, M.A., Seto, E., Young, H.A. and Ye, J. (2005): Coactivators and corepressors of NF-kappaB in IkappaB alpha gene promoter. J. Biol. Chem., 280, 21091-21098.
6. Gregus, Z. and Klaassen, C.D. (2001): Mechanism of toxicity. In Casarett and Doull"s toxicology: The basic science of poisons (Klassen, C.D., ed), pp.35-82, McGraw-Hill, New York.
7. Hodel, C. (2002): Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol. Lett., 128, 159-168.
8. Holz, G.G. (2004): Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes, 53, 5-13.
9. Hunter, R.B. and Kandarian, S.C. (2004): Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. J. Clin. Invest., 114, 1504-1511.
10. Ikeda, A., Sun, X., Li, Y., Zhang, Y., Eckner, R., Doi, T.S., Takahashi, T., Obata, Y., Yoshioka, K. and Yamamoto, K. (2000): p300/CBP-dependent and -independent transcriptional interference between NF-kappaB RelA and p53. Biochem. Biophys. Res. Commun., 272, 375-379.
11. Inoue, I., Itoh, F., Aoyagi, S., Tazawa, S., Kusama, H., Akahane, M., Mastunaga, T., Hayashi, K., Awata, T., Komoda, T. and Katayama, S. (2002): Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem. Biophys. Res. Commun., 290, 131-139.
12. Kovacs, K.A., Steinmann, M., Magistretti, P.J., Halfon, O. and Cardinaux, J.R. (2003): CCAAT/enhancer-binding protein family members recruit the coactivator CREB-binding protein and trigger its phosphorylation. J. Biol. Chem., 278, 36959-36965.
13. Langen, R.C., Schols, A.M., Kelders, M.C., Wouters, E.F. and Janssen-Heininger, Y.M. (2001): Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J., 15, 1169-1180.
14. Madonna, R., Di Napoli, P., Massaro, M., Grilli, A., Felaco, M., De Caterina, A., Tang, D., De Caterina, R. and Geng, Y.J. (2005): Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts. J. Biol. Chem., 280, 13503-13511.
15. Makkinje, A., Quinn, D.A., Chen, A., Cadilla, C.L., Force, T., Bonventre, J.V. and Kyriakis, J.M. (2000): Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in the response to persistent stress. J. Biol. Chem., 275, 17838-17847.
16. Monici, M.C., Aguennouz, M., Mazzeo, A., Messina, C. and Vita, G. (2003): Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology, 60, 993-997.
17. Nakahara, K., Kuriyama, M., Sonoda, Y., Yoshidome, H., Nakagawa, H., Fujiyama, J., Higuchi, I. and Osame, M. (1998): Myopathy induced by HMG-CoA reductase inhibitors in rabbits: A pathological, electrophysiological, and biochemical study. Toxicol. Appl. Pharmacol., 152, 99-106.
18. O'Rourke, J.P., Newbound, G.C., Hutt, J.A. and DeWille, J. (1999): CCAAT/enhancer-binding protein delta regulates mammary epithelial cell G0 growth arrest and apoptosis. J. Biol. Chem., 274, 16582-16589.
19. Owczarek, J., Jasinska, M. and Orszulak-Michalak, D. (2005): Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol. Rep., 57, 23-34.
20. Ritchie, J.W., Baird, F.E., Christie, G.R., Stewart, A., Low, S.Y., Hundal, H.S. and Taylor, P.M. (2001): Mechanisms of glutamine transport in rat adipocytes and acute regulation by cell swelling. Cell. Physiol. Biochem., 11, 259-270.
21. Rosenson, R.S. (2004): Current overview of statin-induced myopathy. Am. J. Med., 116, 408-416.
22. Sheppard, K.A., Rose, D.W., Haque, Z.K., Kurokawa, R., McInerney, E., Westin, S., Thanos, D., Rosenfeld, M.G., Glass, C.K. and Collins, T. (1999): Transcriptional activation by NF-kappaB requires multiple coactivators. Mol. Cell Biol., 19, 6367-6378.
23. Takahashi, N., Tetsuka, T., Uranishi, H. and Okamoto, T. (2002): Inhibition of the NF-kappaB transcriptional activity by protein kinase A. Eur. J. Biochem., 269, 4559-4565.
24. Tanaka, K., Watanabe, T., Sharyo, S., Ohashi, Y., Takaoka, M. and Manabe, S. (2005): Acquired resistance to bromobenzene hepatotoxicity by repeated treatment of rats with bromobenzene. J.Toxicol. Pathol., 18, 189-198.
25. Thompson, P.D., Clarkson, P. and Karas, R.H. (2003): Statin-associated myopathy. JAMA, 289, 1681-1690.
26. Tsunoda, T., Inokuchi, J., Baba, I., Okumura, K., Naito, S., Sasazuki, T. and Shirasawa, S. (2002): A novel mechanism of nuclear factor kappaB activation through the binding between inhibitor of nuclear factor-kappaBalpha and the processed NH(2)-terminal region of Mig-6. Cancer Res., 62, 5668-5671.
27. Uchiyama, T., Matsuda, Y., Wada, M., Takahashi, S. and Fujita, T. (2005): Functional regulation of Na+-dependent neutral amino acid transporter ASCT2 by S-nitrosothiols and nitric oxide in Caco-2 cells. FEBS Lett., 579, 2499-2506.
28. von Keutz, E. and Schluter, G. (1998): Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor. Am. J. Cardiol., 82, 11J-17J.
29. Waclawik, A.J., Lindal, S. and Engel, A.G. (1993): Experimental lovastatin myopathy. J. Neuropathol. Exp. Neurol., 52, 542-549.
30. Zwergal, A., Quirling, M., Saugel, B., Huth, K.C., Sydlik, C., Poli, V., Neumeier, D., Ziegler-Heitbrock, H.W. and Brand, K. (2006): C/EBP beta blocks p65 phosphorylation and thereby NF-kappa B-mediated transcription in TNF-tolerant cells. J. Immunol., 177, 665-672.